Intervacc’s Chief Scientific Officer Dr Andrew Waller presents at the Veterinary Sport Horse Congress in Amsterdam

“It’s a fantastic opportunity to speak about strangles directly to this important group of equine professionals”, says Dr Andrew Waller, Chief Scientific Officer at Intervacc. “During 2022 Sport Horses were identified as the breed most at risk of being diagnosed with strangles, accounting for 37% of all strangles diagnoses in the UK. I’m incredibly excited about highlighting the new tools available to prevent this terrible disease and protect these amazing athletes as they participate in equestrian events throughout the world.”

Dr Andrew Waller studied the evolution, transmission, and prevention of Streptococcus equi and Streptococcus zooepidemicus for over 17 years in his role as Head of Bacteriology at the Animal Health Trust. He collaborates with world leading researchers in over 20 countries around the world, has published over 80 peer-reviewed papers on streptococcal infections of animals and has utilised these research findings to develop novel diagnostic tests and vaccines with which to improve animal health. Andrew joined Intervacc in 2020 where he continues to work towards improving the health of animals.

Strangles, caused by Streptococcus equi, remains one of the most prevalent infectious diseases of horses worldwide. The transmission of S. equi is facilitated by its ability to persist within the guttural pouches of recovered horses, presenting a challenge to the diagnosis, treatment, and prevention of infection. Andrew’s presentation will describe how this host-restricted pathogen establishes infection and evades host immune responses to be transmitted to naïve animals. The diagnosis, treatment, and prevention of strangles provide opportunities to break the cycle of infection towards the eradication of S. equi from premises with endemic infection. Andrew will describe the latest advances in diagnostic and preventative measures towards improving the health of horses.

For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on January 23, 2023, 15.45 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10